Because the super-contagious delta variant started to unfold broadly, scientists at BioNTech, the Germany-based firm that partnered with Pfizer to make the primary accepted COVID-19 vaccine, went into the lab to rapidly create a new model of the vaccine that particularly focused the variant. As a result of the corporate makes use of mRNA know-how—a sort of vaccine that makes ...